---
title: "Levima: The company has completed the development of PEEK-related technology and product pilot testing, and is advancing industrialization"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256691772.md"
description: "Levima responded on the interactive platform on September 10th, stating that PEEK-related materials are one of the key products the company focuses on and researches. The company has currently completed the technical development and pilot testing of PEEK-related products and is advancing towards industrialization"
datetime: "2025-09-10T08:18:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256691772.md)
  - [en](https://longbridge.com/en/news/256691772.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256691772.md)
generator: "portal-rs"
---

# Levima: The company has completed the development of PEEK-related technology and product pilot testing, and is advancing industrialization

On September 10th, Levima responded on the interactive platform stating that PEEK-related materials are one of the key products the company focuses on and researches. The company has currently completed the technical development and pilot testing of PEEK-related products and is advancing towards industrialization

### Related Stocks

- [003022.CN](https://longbridge.com/en/quote/003022.CN.md)

## Related News & Research

- [TMP Group designs, builds Parma Calcio-AdmiralBet.news hospitality areas at Tardini stadium](https://longbridge.com/en/news/296793284.md)
- [Cocoa Prices Fall on Rising Nigerian Cocoa Exports](https://longbridge.com/en/news/296637826.md)
- [Danantara Sumberdaya Indonesia is identifying commodity export inconsistencies, chief says](https://longbridge.com/en/news/296773364.md)
- [One seemingly ordinary job has gotten much more deadly over the past 10 years, federal data shows](https://longbridge.com/en/news/296704689.md)
- [CTT Pharmaceutical CEO Ryan Khouri acquires 10,000 common shares for $590](https://longbridge.com/en/news/296370127.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**